Your browser doesn't support javascript.
Side effects of messenger RNA vaccines and prior history of COVID-19, a cross-sectional study.
Kadali, Renuka Ananth Kalyan; Janagama, Ravali; Yedlapati, Siva H; Kanike, Neelakanta; Gajula, Viswanath; Madathala, Rajasekhar R; Poddar, Swati; Sukka, Neelakanta; Jogu, Hanumantha R; Racherla, Shailaja; Shah, Isha.
  • Kadali RAK; Department of Internal Medicine, Harnett Hospitalist Group, Campbell University Jerry M. Wallace School of Osteopathic Medicine, Lillington, NC. Electronic address: Renuka.Kadali@harnetthealth.org.
  • Janagama R; Department of Pediatrics, Kidzcare Pediatrics, Sanford, NC.
  • Yedlapati SH; Department of Internal Medicine, Erie County Medical Center, Buffalo, NY.
  • Kanike N; Division of Neonatology, Department of Pediatrics, Indiana University School of Medicine, Newburgh, IN.
  • Gajula V; Division of Pediatric Critical Care Medicine, Department of Pediatrics, The University of Mississippi Medical Center, Jackson, MS.
  • Madathala RR; Department of Internal Medicine, Mayo Clinic, Rochester, MN.
  • Poddar S; Psychiatry Program, California Health Care Facility, Stockton, CA.
  • Sukka N; Department of Internal Medicine, Vidant medical group, Lenoir Memorial hospital, Kinston, NC.
  • Jogu HR; Department of Internal Medicine, Vidant medical group, Greenville, NC.
  • Racherla S; Department of Pathology and Laboratory Medicine, University of California, Davis, CA.
  • Shah I; Rheumatology Program, Kent Hospital, Warwick, Rhode Island, USA.
Am J Infect Control ; 50(1): 8-14, 2022 01.
Article in English | MEDLINE | ID: covidwho-1487574
ABSTRACT

BACKGROUND:

There are concerns regarding immunogenicity with coronavirus disease 2019 (COVID-19) mRNA vaccines among persons with prior history of COVID-19 (PHC). This study was to analyze the short-term side effects of mRNA vaccines among health care workers (HCWs) with and without PHC.

METHODS:

A cross-sectional study was performed using an independent online survey questionnaire that gathered responses from HCWs.

RESULTS:

Among 1,475 HCWs, 1268 (85.97%) completed the survey, 102/1268 (44/447 in Moderna group and 58/821 in Pfizer-BioNTech group) reported PHC during pre-vaccination period. Symptoms of flushing/P = .05, brain fogging/P= .005, vertigo/P= .041, numbness/P= .023, diarrhea/P= .047, hives/P= .028, itching/P= .028, swelling of lips/mouth/P= .001, shortness of breath/P= .022, and anxiety/P= .048 have greater occurrence among Pfizer-BioNtech group with PHC when compared to Pfizer-BioNtech group with no PHC. Symptoms of chills/P= .027, flushing/P= .045, tremor/P= .05, muscle spasm/P= .039, vomiting/P= .031, diarrhea/P= .015, and cough/P= .011 have higher occurrence among Moderna group with PHC when compared to Moderna group with no PHC.

CONCLUSIONS:

Few short-term side effects among mRNA vaccine recipients with PHC may have necessitated transient time-off from work. The PHC can be considered as a predictor for severity of side effects. While the vaccination program continues in the United States, a future COVID legislation that mandates vaccination among employees along with paid time off provision may help with higher compliance and acceptance.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / MRNA Vaccines Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Am J Infect Control Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / MRNA Vaccines Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Am J Infect Control Year: 2022 Document Type: Article